Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Infectious Disease/Septic Shock

Infectious Disease

Septic Shock

55

Pipeline Programs↗

55

Active Trials↗

24

Companies Involved↗

Septic Shock is a moderately active landscape with 55 programs across 24 companies. 11 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

60/100

Mech. Concentration

14/100

Completion Rate

78/100

Attrition Rate

13/100

Pipeline

Programs by Phase

Preclinical40

Daptomycin

Baxter Healthcare Corporation

Doripenem

Shionogi

Imipenem

Pfizer

Metformin

EMD Serono

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

No programs

Phase 24

Nangibotide

Inotrem

Epinephrine

Samson Clinical Operations Pty Ltd

Sevoflurane

AbbVie

ARTICE

Artcline GmbH

Phase 311

Hydrocortisone Sodium Succinate

National Cancer Institute (NCI)

Esmolol

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Methylene Blue

Provepharm SAS

Landiolol

Aultman Health Foundation

Fludrocortisone

Jazz Pharmaceuticals

Approved

No programs

Analysis

Modality Breakdown

96%

Small molecule

49 of 51 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 51 classified programs, each share of the total. Modality classified for 100% of 55 pipeline programs.

Analysis

Trial Status

300

clinical trials

Completed144 · 48%

Unknown status60 · 20%

Terminated27 · 9%

Recruiting27 · 9%

Not yet recruiting24 · 8%

Withdrawn12 · 4%

Other6 · 2%

Clinical Trials

Trial Activity

300 trials

Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients

Recruiting·—·Preclinical·NCT06140147·1,850 enrolled

Effect of the oXiris Hemofilter on Early Endotoxin Burden in Patients With Septic Shock Requiring Continuous Renal Replacement Therapy: A Single-Center, Prospective, Single-Arm Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Preclinical·NCT07807410·13 enrolled

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

Recruiting·—·Approved·NCT06693726·20 enrolled

Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial

Recruiting·UUniversity Hospital, Strasbourg, France·Approved·NCT06881927·212 enrolled

Discordance Between Capillary Refill Time and Oxygen Extraction Ratio in Septic Shock: A Prospective Observational Cohort Study Evaluating Its Prevalence and Prognostic Value

Recruiting·IIstanbul University - Cerrahpasa·N/A·NCT07774962·100 enrolled

Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study: MEFDASE Study

Recruiting·UUniversity Hospital, Angers·N/A·NCT04288635·55 enrolled

Albumin and Crystalloid Administration in Septic Shock (ALCAMIST): Multi-center, Open Labelled Randomized Controlled Trial

Recruiting·AAsan Medical Center·Approved·NCT05148286·2,426 enrolled

Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration

Recruiting·HHospices Civils de Lyon·N/A·NCT04067674·305 enrolled

Association Between Muscle L3 CT Scan Muscle Derived Parameters of Muscle Function Upon Intensive Care Unit Admission and 3 Months Mortality After ICU Discharge for Patients Admitted for Septic Shock. The SIMS Study

Recruiting·CCentre Hospitalier Universitaire de Saint Etienne·Preclinical·NCT07483710·196 enrolled

The MARINA Study: bioMArkeRs of INflammation, Infection, and Immunity in the Critical Area: the Use of Inflammatory and Immunity Biomarkers as Early Predictors of Clinical Severity, Organ Damage, Response to Treatment, and Infectious Complications in Patients Admitted to the Critical Care Area.

Recruiting·UUniversity of Turin, Italy·N/A·NCT07682766·200 enrolled

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

Recruiting·BBluejay Diagnostics, Inc.·N/A·NCT07425587·450 enrolled

Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy

Recruiting·AArtcline GmbH·Phase 2·NCT05442710·142 enrolled

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

Recruiting·—·Phase 4·NCT06670963·200 enrolled

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock

Recruiting·OOttawa Hospital Research Institute·Phase 2·NCT05969275·296 enrolled

Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

Recruiting·—·N/A·NCT07255378·1,200 enrolled

Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)